BioDirt's 2026 Update 🧬

It’s been a while, and I have some thoughts...

Let’s jump straight in.

In 2026, the biotech industry is witnessing a fundamental shift in real estate requirements, moving away from the traditional "human-centric" bench model toward a modular, machine-first infrastructure.

The rise of Physical AI—the integration of AI models with robotic hardware to perceive and manipulate the physical world—is redefining how lab space is designed, powered, and leased.

1. The Footprint of the "Self-Driving Lab"

The most significant change is the emergence of Self-Driving Labs (SDLs). These are autonomous discovery systems where AI plans experiments, robots execute them, and the AI analyzes the results to iterate on the next cycle without human intervention.

• Modular Pods vs. Continuous Benches: Traditional fixed lab benches are being ripped out in favor of modular robotic pods. These pods can be reconfigured in hours rather than months, allowing a lab to pivot from oncology research to synthetic biology with minimal downtime.

• Robotic "Tracks": High-ceilinged facilities are now prioritized to accommodate ceiling-mounted robotic arms and overhead tracks, which allow mobile robots to move samples between different instruments (incubators, sequencers, and mass specs) across the entire floor.

• Reduced "Ergonomic" Space: As robots take over liquid handling and sample prep, the need for human-sized aisles and ergonomic bench heights is decreasing, allowing for higher-density equipment clustering.

2. Infrastructure 4.0: Power and Data

Physical AI requires significantly more "under-the-hood" infrastructure than a standard 20th-century wet lab.

• Compute-Heavy Heat Loads: Physical AI units often have dedicated on-site edge computing to process visual data and motion planning in real-time. This has led to a 25% to 40% increase in cooling requirements (HVAC) compared to traditional labs.

• The "Wireless" Lab: New lab designs in 2026 feature embedded sensors in ceilings and service spines to support IoT-enabled instrumentation. We are seeing a move toward wireless power zones and 6G/low-latency networking to ensure robotic agents can communicate with "digital twins" of the lab without data lag.

• Acoustic & Vibration Zoning: Robotic systems are inherently noisy and cause micro-vibrations. New lab designs use acoustic zoning to separate the "machine room" (robotic high-throughput screening) from quiet analytical areas where scientists perform data interpretation.

3. The Hybridization of Space (Wet vs. Dry)

The distinction between the "Wet Lab" (biological work) and the "Dry Lab" (computational work) is dissolving.

• "In-Silico" Integration: Every physical workstation now effectively has a "computational twin." Real estate demand is shifting toward Hybrid Flex Space, where high-performance computing (HPC) clusters are located adjacent to the bioreactors they monitor.

• Collaboration Hubs: Since the "bench work" is increasingly automated, the human footprint is shifting toward Innovation Destinations. Biotech companies are seeking smaller total square footage but higher-quality "write-up" spaces, rooftop terraces, and decompression rooms to attract top-tier talent who now spend their days designing AI prompts rather than pipetting.

4. Impact on the Real Estate Market

This shift has stabilized the 2026 life sciences market after a period of oversupply.

• Specialized Demand: There is a surge in demand for Advanced Manufacturing & Robotics spaces. Traditional office buildings that were converted to labs in the 2021-2023 boom are often finding themselves "under-powered" for the 2026 Physical AI requirements, leading to a premium for purpose-built "AI-ready" facilities.

• Regional Hubs: While Cambridge and South San Francisco remain leaders, new "Physical AI Hubs" are emerging in cities like Austin and Pittsburgh, where robotics expertise is more accessible and real estate allows for the large-scale "biofoundries" required for autonomous research.
  (sources: Area Laboratories and BaneBio)

-Ted Simpson

BIOTECH FIELD TRIP

I recently attended the LABest Bioscience conference at the UCLA Digital & Technology Solutions Development Group on the Westwood campus. For me, the highlight was brief pitches by biotech entrepreneurs to a panel of potential investors (think Shark Tank). These young PhDs were all trying to solve some of the biggest threats to human health. Needless to say, it made me excited about our future, and I wanted to see each of them get funded. Here are just a few:

Konstantin Kazarian, PhD, Hybrid Biotherapeutics Inc.
Zipeng Zeng, PhD, DeepNephro Inc.
Benjamin Tully, Branchpoint Biosciences
Samuel Lobo, ProFoldBio
Hairuo Guo and Theodosia Bartashevitch, Holomorph Bio
Adam Klie, Gaius Therapeutics
Kathleen Sicinski, PhD, Censera
Wael El-Nachef, Angel City Bio 

For more info on these companies, go here.

One of these brilliant scientists will find a cure for cancer, Alzheimer's/dementia, or another chronic disease. Now I'm just figuring out what I'll be doing at 100 – maybe leasing lab space to their biotech companies!

UCLA’S RESEARCH PARK UPDATE

UCLA Research Park, which will include two wings at 10800 and 10850 W. Pico Boulevard, will have approximately 800,000 square feet of space through a combination of adaptive reuse and new construction. Those uses include:

• 271,000 square feet of wet and dry laboratories;

• 214,000 square feet of offices;

• 52,400 square feet of meeting areas,

• 258,700 square feet of common areas, circulation areas, and back of house functions; and

• 14,700 square feet of food service areas.

Plans also call for more than 29,000 square feet of open space and outdoor amenities across the more than nine-acre site, and room for 1,100 parking spaces. You can learn more here: Urbanize Los Angeles.

REAL ESTATE MARKET ACTIVITY OF NOTE

Xencor subleased 46,143 RSF of its surplus space on Halston to Leon Max (a fashion company) in January 2026. 5-year term. Removes potential lab space from the market.  Xencor had approximately 120,000 SF and remains in the building.

Alexandria’s Innovation Center at 129 N Hill Ave in Pasadena is 100% vacant. It’s a one-story 46,765 SF building.

Some highlights:

• Fully built out lab suite with lab benches, epoxy countertops and sinks

• Glass wash station, RODI water

• Single-pass air, Gas and vacuum systems

• 12 fume hoods (building total); capacity for additional emergency shower and eyewash stations, BSL-2+ capability

Reach out if you’d like a tour.

BIOTECH MARKET UPDATE

The biopharma industry entered 2026 with renewed momentum in dealmaking. But venture capital (VC) investors maintained their cautious stance on early-stage innovation. JPMorgan's Q1 2026 Biopharma Licensing and Venture Report showed selective strength across licensing and M&A activity. Meanwhile, venture funding patterns revealed a widening gap between early and late-stage capital allocation. Biopharma licensing partnerships reached $82.7 billion in announced value during Q1 2026, underscoring the industry's continued appetite for external innovation. However, the deal structures tell a more nuanced story: upfront cash represented just 6% of total deal value, signaling that risk is being firmly pushed into milestone-based back-end payments. (source: BioXconomy)

The share price of Thousand Oaks-based immunotherapy company Atara Biotherapeutics nearly doubled on May 7 after a welcome dose of positive news.The company reported that the U.S. Food and Drug Administration has laid out a path for resubmission of Atara’s cell therapy drug candidate that the agency had twice before rejected. Shareholder jubilation was immediate. Within hours, Atara’s stock had nearly doubled to $10 a share. The price closed on May 7 at $9.93 – up 93% – with a record volume of 77 million shares. The stock slipped a bit in the following days though rebounded on May 13, a day after the company’s earnings release, closing at $10.48. The price still remains below the $14 to $18 range the stock was trading before news of the FDA’s second rejection hit in early January. (source: Valley Business Journal)

IBB (biotech ETF) is almost back to the post-COVID peak. You can check out the chart here.

Thanks for reading. If you want me to look into something or have some ideas for the newsletter, reach out, and I’ll get right back to you.

And, as always, we're here to help you with your real estate needs.

Ted Simpson
Founder and CEO
Commercial Real Estate Advisors
(c) +1 310.384.6512
(e) [email protected]
CA DRE License #0109718

P.S. Whenever you’re ready, here are 3 ways I can help you with your real estate.

1. A new home for your business. So, you want to move, but you don’t know the market. I can help.

2. Time to renew your lease? Don’t quite trust your landlord? Consider me your personal polygraph. BTW, I recommend starting the lease renewal process six months out at a minimum.

3. Sublease your space. You’ve outgrown your space and need to move but don’t want to pay two rents? I got you.